Improving the outcome of relapsed or refractory diffuse large B-cell lymphoma(R/R DLBCL)remained an unmet need.The aim of this single-center,phase 2 trial was to evaluate the efficacy and safety of genetic subtype-gui...Improving the outcome of relapsed or refractory diffuse large B-cell lymphoma(R/R DLBCL)remained an unmet need.The aim of this single-center,phase 2 trial was to evaluate the efficacy and safety of genetic subtype-guided immunochemotherapy(R-ICE-X)in patients with R/R DLBCL:R-ICE-zanubrutinib for MCD-like and BN2-like,R-ICE-lenalidomide for N1-like and NOS,R-ICE-decitabine for TP53^(Mut),R-ICE-chidamide for EZB-like,and R-ICE-tofacitinib for ST2-like subtype.Enrolled patients were treated with assigned regimens for three cycles,and then responders were treated with autologous hematopoietic stem cell transplantation(ASCT)or 3 cycles of R-ICE-X consolidation and lenalidomide maintenance.The primary endpoint was the complete response(CR)rate.展开更多
基金supported by research funding from the National Key R&D Program of China(2023YFC3605704,2022YFC2502600)the National Natural Science Foundation of China(82130004,82170178,82200201,82070204)+6 种基金the Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine(DLY201601)the Chang Jiang Scholars Program,the Clinical Research Plan of Shanghai Hospital Development Center(SHDC2020CR1032B)Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support(20152206,20152208)the Multicenter Hematology-Oncology Program Evaluation System(M-HOPES)the Shanghai Sailing Program(23YF1423700)the Collaborative Innovation Center of Systems Biomedicinethe Samuel Waxman Cancer Research Foundation.
文摘Improving the outcome of relapsed or refractory diffuse large B-cell lymphoma(R/R DLBCL)remained an unmet need.The aim of this single-center,phase 2 trial was to evaluate the efficacy and safety of genetic subtype-guided immunochemotherapy(R-ICE-X)in patients with R/R DLBCL:R-ICE-zanubrutinib for MCD-like and BN2-like,R-ICE-lenalidomide for N1-like and NOS,R-ICE-decitabine for TP53^(Mut),R-ICE-chidamide for EZB-like,and R-ICE-tofacitinib for ST2-like subtype.Enrolled patients were treated with assigned regimens for three cycles,and then responders were treated with autologous hematopoietic stem cell transplantation(ASCT)or 3 cycles of R-ICE-X consolidation and lenalidomide maintenance.The primary endpoint was the complete response(CR)rate.
